Stock 603127 JOINN LABORATORIES(CHINA)CO.,LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Joinn Laboratories(China)Co.,Ltd.

Equities

603127

CNE100002W27

Biotechnology & Medical Research

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
17.37 CNY +2.72% Intraday chart for Joinn Laboratories(China)Co.,Ltd. +3.52% -26.74%
Apr. 03 Tranche Update on Joinn Laboratories(China)Co.,Ltd.'s Equity Buyback Plan announced on April 3, 2024. CI
Apr. 03 Joinn Laboratories(China)Co.,Ltd. announces an Equity Buyback for CNY 100 million worth of its shares. CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 9,347 23,453 40,246 29,328 16,313 11,998 - -
Enterprise Value (EV) 1 9,347 23,453 36,161 26,442 13,478 8,676 8,322 7,323
P/E ratio 52.5 x 74.2 x 77 x 29.2 x 44.7 x 25.3 x 19.4 x 19.3 x
Yield 0.59% - 0.31% 0.68% 0.67% 0.97% 1.15% 1.53%
Capitalization / Revenue 14.6 x - 26.5 x 12.9 x 6.86 x 4.98 x 4.16 x 4.13 x
EV / Revenue 14.6 x - 23.8 x 11.7 x 5.67 x 3.6 x 2.89 x 2.52 x
EV / EBITDA - - 71 x 19.8 x 21.5 x 11.8 x 9.11 x 8.24 x
EV / FCF - - 80.8 x 38 x 31.3 x 11.6 x 16.2 x 18.5 x
FCF Yield - - 1.24% 2.63% 3.19% 8.63% 6.18% 5.41%
Price to Book 11.3 x - 6.16 x 3.82 x 2.15 x 1.5 x 1.38 x 1.34 x
Nbr of stocks (in thousands) 621,252 624,136 747,243 749,950 746,974 746,974 - -
Reference price 2 15.05 37.58 58.89 41.72 23.71 17.37 17.37 17.37
Announcement Date 4/12/20 3/29/21 2/24/22 3/30/23 3/28/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 639.4 - 1,517 2,268 2,376 2,409 2,884 2,908
EBITDA 1 - - 509.1 1,333 626.1 737.8 913.1 889
EBIT 1 206.1 - 407.6 1,226 507.1 587.4 774 800.7
Operating Margin 32.24% - 26.88% 54.04% 21.34% 24.38% 26.84% 27.54%
Earnings before Tax (EBT) 1 205.9 - 642 1,240 507 534.7 768.5 799.1
Net income 1 178.4 315 557.5 1,074 397 514.1 673.3 675
Net margin 27.9% - 36.76% 47.37% 16.71% 21.34% 23.35% 23.22%
EPS 2 0.2863 0.5066 0.7653 1.429 0.5300 0.6857 0.8975 0.8996
Free Cash Flow 1 - - 447.4 696.3 430.3 748.6 514.7 396.1
FCF margin - - 29.5% 30.7% 18.11% 31.07% 17.85% 13.62%
FCF Conversion (EBITDA) - - 87.88% 52.25% 68.73% 101.46% 56.37% 44.55%
FCF Conversion (Net income) - - 80.26% 64.82% 108.39% 145.62% 76.45% 58.67%
Dividend per Share 2 0.0885 - 0.1837 0.2857 0.1600 0.1688 0.2000 0.2656
Announcement Date 4/12/20 3/29/21 2/24/22 3/30/23 3/28/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2022 S2 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 - - 499.5 991.6 1,491 369.4 642.7 575 789.4 397 692 635 842
EBITDA - - 168.6 - - - - - - - - - -
EBIT - - 297.1 507.9 805 214.4 - 275.2 115 - - - -
Operating Margin - - 59.48% 51.22% 53.99% 58.03% - 47.87% 14.57% - - - -
Earnings before Tax (EBT) - - - 507.8 804.9 214.3 -97.39 275 115 - - - -
Net income 125.3 245.8 260.9 442.2 703.1 187.8 -97.13 237 69.39 - - - -
Net margin - - 52.23% 44.6% 47.16% 50.83% -15.11% 41.21% 8.79% - - - -
EPS 2 0.1684 - 0.3500 0.5857 - 0.2500 -0.0800 0.3200 0.0900 0.0300 0.1000 0.0800 0.1000
Dividend per Share 2 - - - - - - - - - - - - 0.1610
Announcement Date 4/28/22 8/30/22 10/28/22 3/30/23 3/30/23 4/27/23 8/30/23 10/30/23 3/28/24 - - - -
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 - - 4,085 2,886 2,835 3,322 3,676 4,675
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 - - 447 696 430 749 515 396
ROE (net income / shareholders' equity) 24.4% 30.8% 13.3% 14% 4.82% 6.01% 6.97% 6.9%
ROA (Net income/ Total Assets) 13.9% - 10.4% 11.4% - 4.16% 5.01% 5.21%
Assets 1 1,280 - 5,355 9,451 - 12,370 13,432 12,951
Book Value Per Share 2 1.330 - 9.560 10.90 11.00 11.60 12.60 13.00
Cash Flow per Share 2 0.2400 - 0.9400 1.290 0.8300 1.040 0.8500 1.190
Capex 1 127 - 237 275 193 197 207 178
Capex / Sales 19.83% - 15.64% 12.11% 8.1% 8.17% 7.16% 6.12%
Announcement Date 4/12/20 3/29/21 2/24/22 3/30/23 3/28/24 - - -
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Joinn Laboratories(China)Co.,Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
17.37 CNY
Average target price
19.29 CNY
Spread / Average Target
+11.06%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
JOINN LABORATORIES(CHINA)CO.,LTD. Stock Joinn Laboratories(China)Co.,Ltd.
-26.74% 1.66B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. 603127 Stock
  4. Financials Joinn Laboratories(China)Co.,Ltd.